Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639135 | 0.86 | ALDH1A1 (0.35) | ALDH1A1TSHREPHX2TDP1CYP1A2 | |
| SCHEMBL12023038 | 0.83 | TSHR (0.46) | ALDH1A1TSHRTHRBTDP1CYP1A2 | |
| SCHEMBL17599662 | 0.83 | TDP1 (0.32) | ALDH1A1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5596714 | 0.82 | TDP1 (0.31) | TDP1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17613680 | 0.82 | TDP1 (0.31) | RAB9ATDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17613625 | 0.81 | — | — | |
| SCHEMBL17613644 | 0.81 | TDP1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL17991048 | 0.80 | THRB (0.37) | TSHRTHRBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5596366 | 0.79 | TDP1 (0.32) | ALDH1A1TDP1 | |
| SCHEMBL19543508 | 0.78 | LPAR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796336-B2 | Methoxypolyethylene glycol chelate and uses thereof | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120016030-A1 | METHOXYPOLYETHYLENE GLYCOL THIOESTER CHELATE AND USES THEREOF | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2012-01-19 | — | — | US | disclosed |
| US-8008347-B2 | Methoxypolyethylene glycol thioester chelate and uses thereof | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306205-A1 | METHOXYPOLYETHYLENE GLYCOL THIOESTER CHELATE AND USES THEREOF | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-12-10 | — | — | US | disclosed |
| US-7388028-B2 | Methoxypolyethylene glycol thioester chelate and uses thereof | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080039524-A1 | Methoxypolyethylene glycol thioester chelate and uses thereof | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306205-A1 | METHOXYPOLYETHYLENE GLYCOL THIOESTER CHELATE AND USES THEREOF | MGST3, MGMT, HAGH | ALDH1A1 3018/4885TSHR 1062/4885THRB 2079/4885 |
| US-20080039524-A1 | Methoxypolyethylene glycol thioester chelate and uses thereof | MGST3, MGMT, MBOAT1 | ALDH1A1 3158/4885TSHR 1036/4885THRB 2087/4885 |
| US-20120016030-A1 | METHOXYPOLYETHYLENE GLYCOL THIOESTER CHELATE AND USES THEREOF | MGST3, MGMT, MBOAT1 | ALDH1A1 3158/4885TSHR 1036/4885THRB 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.